Allied Market Research
Loading...
0
New
New
2021
Narcolepsy Drugs Market

Narcolepsy Drugs Market by Disease (Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type) and Therapeutic Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type): Global Opportunity Analysis and Industry Forecast, 2021-2030

A03272
Pages: 198
Sep 2021 | 9690 Views
   
Author(s) : Kishor Sherkar, Deepshikha Singh , Onkar Sumant
Tables: 91
Charts: 38
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Narcolepsy Drugs Market

Request Now !

Narcolepsy Drugs Market Overview

The global narcolepsy drugs market size was valued at $2,680.06 million in 2020, and is projected to reach $6,667.80 million by 2030, registering a CAGR of 9.6% from 2021 to 2030. Narcolepsy is a chronic sleep disorder that affects the brain’s ability to control sleep-wake cycles. It is characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often find it difficult to stay awake for long periods of time and feel very sleepy throughout much of the day.

COVID Banner Statement: The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the narcolepsy drugs market. The continuous spread of the COVID-19 pandemic and the measures taken by the governments of various countries have affected, and could continue to affect, the businesses, including future disruptions to supply chain and the manufacture or shipment of drug substance and finished drug products. In addition, delays by manufacturers or their partners in the initiation or enrollment of patients in clinical trials, discontinuations by patients enrolled in clinical trials, difficulties launching or commercializing products and other related activities, which could delay ongoing clinical trials, increase development costs, reduce royalty revenues and have a material adverse effect on manufacturers’ business, financial condition and results of operations.

Many individuals with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night. Narcolepsy can affect daily life activities of the sufferers. People with narcolepsy may unwillingly fall asleep in the middle of an activity like driving, eating, or talking. It is usually the first symptom to appear and is often the most troublesome, making it difficult to concentrate on certain activities. Other symptoms include sudden muscle weakness while awake that makes a person go limp or unable to move (cataplexy). Narcolepsy is a lifelong problem and cannot get cured completely but symptoms can partially improve over time with proper medications and lifestyle changes. Increasing stress among individuals consequently leads to a stressful lifestyle and increase in consumption of alcohol, tobacco, and other harmful addictive’s is expected to increase the risk of narcolepsy. Drug development for narcolepsy treatment has gained incredible momentum the past few years. In addition, governments of countries such as India and South Africa are promoting the production of narcolepsy drug considering its health benefits, which is further expected to boost the narcolepsy drug market growth during the forecast period. Moreover, high disposable income and an increase in awareness about the benefits of narcolepsy drugs are anticipated to boost the growth of the market. However, lower stability, poor sustainability of natural colors derived from narcolepsy drug as compared to synthetic colors, and lack of awareness regarding the diagnosis and treatment availability is predicted to hinder the market growth. There is an increase in the number of programs organized by various organizations mainly to increase the awareness, which is anticipated to provide lucrative opportunities for the narcolepsy drugs market growth.          

narcolepsy-drugs-market--2020-2030 

Get more information on this report : Request Sample Pages

COVID-19 Impact

Coronavirus (COVID-19) was recognized in late December in Hubei province of Wuhan city in China. This highly contagious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from humans to humans. The COVID-19 pandemic has resulted in nationwide lockdowns, thereby impacting every industry vertical. According to the report of the United Nations Human Rights, the COVID-19 pandemic has threatened all the members of the society. As a result, health care systems are affected, and the effective delivery of medical care and treatment to all patients has become a challenge worldwide. The COVID-19 pandemic is an unprecedented global public health challenge, during the pandemic, global healthcare systems faced many difficult challenges due to severe shortages of hospital beds and medical equipment, patient suffering from COVID-19 having acute respiratory distress syndrome (ARDS) and these patients requires high-level respiratory support to survive.  The social isolation and interruption of daily routines resulting from COVID-19 precautions may impact individuals’ exposure to the light-dark cycle that regulates the circadian system, and thereby exacerbate existing narcolepsy symptoms. Furthermore, the altered bedtime schedules were associated with an increase in excessive daytime sleepiness, which may in turn explain the increase in the use of stimulants. The impact of COVID-19 on narcolepsy drugs was negative during pandemic. The most significant difficulty is that, the patients with narcolepsy may fail to get their prescription due to the restrictions on public transport, home quarantine, and fear of cross-infection in hospitals, resulting in drug discontinuation. Moreover, due to lack of appropriate treatment available for COVID-19, the manufactures and industries are focusing more on the production of the drugs and equipment’s which are needed for the treatment of COVID-19. Lately, there is not sufficient personal protective equipment (PPE) for hospital workers on the front lines in this terrifying time. All around the world, hospitals are overwhelmed by the volume of patients and the lack of personal protective equipment including face masks, gloves, eye protection and clothing.

Disease Type Segment Review

By disease type, the narcolepsy drugs market is categorized into excessive day time sleepiness, cataplexy, and other disease type. The excessive day time sleepiness segment dominates the narcolepsy drugs market. Moreover, drug development for narcolepsy treatment has gained incredible momentum the past few years. Governments of countries such as India and South Africa are promoting the production of narcolepsy drug considering its health benefits, which is further expected to boost the narcolepsy drug market growth.

Narcolepsy Drugs Market
By Disease Type

Your browser does not support the canvas element.

Daytime Extreme Sleepiness segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Therapeutic Type Segment Review

By therapeutic type, the narcolepsy drugs market is segmented into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and other therapeutic type. The sodium oxybate segment dominated the narcolepsy drugs market in 2020 owing to its widespread use in the treatment of narcolepsy symptoms.

Narcolepsy Drugs Market
By Therapeutic Type

Your browser does not support the canvas element.

Sodium Oxybate sleepiness segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Regional Review:

North America spearheaded the narcolepsy drugs market in 2020 and is expected to continue this dominance throughout the forecast period. This is attributed to increase in R&D activities and numerous collaborations between academic and commercial organizations in this region. Increase in acquisition, product launch, and product approval by key players of this market operate in North America turn, fuels growth of the market.

Narcolepsy Drugs Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

This report provides comprehensive competitive analysis and profiles of prominent market players such as Arena Pharmaceuticals, Inc., Bioprojet Company, Graymark Healthcare, Inc., Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Shionogi Inc., Takeda Pharmaceutical Company Limited, Novartis International AG, and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current narcolepsy drugs market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing narcolepsy drugs market opportunities.
  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
  • The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the Narcolepsy drugs market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the Narcolepsy drugs market.

Key Market Segments

  • By Disease Type
    • Daytime Extreme Sleepiness
    • Cataplexia
    • Other Disease Type
  • By Therapeutics Type
    • Central Nervous System Stimulants
    • Tricyclic Antidepressants
    • Sodium Oxybate
    • Selective Serotonin Reuptake Inhibitor
    • Other Therapeutic Type
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi
      • South Africa
      • Rest of LAMEA


Key Market Players

  • ARENA PHARMACEUTICAL, INC.
  • BIOPROJET PHARMA SARL
  • JAZZ PHARMACEUTICAL PLC
  • LIGAND PHARMACEUTICALS INCORPORATED
  • NOVARTIS INTERNATIONAL AG
  • SHINOGI INC.
  • TAKEDA PHARMACEUTICAL COMPANY
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics

3.5.1.Drivers, restraints, and opportunity
3.5.2.Drivers

3.5.2.1.Increase in global prevalence of narcolepsy
3.5.2.2.Narcolepsy awareness programs and services
3.5.2.3.Presence of reimbursement policies regarding narcolepsy

3.5.3.Restraints

3.5.3.1.Adverse effects and risks related to narcolepsy drugs
3.5.3.2.Delayed diagnosis or misdiagnosis

3.5.4.Opportunity

3.5.4.1.Untapped markets in the developing countries

3.6.Impact of COVID-19 on the NARCOLEPSY DRUG market

3.6.1.Overview
3.6.2.Impact analysis

CHAPTER 4:NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Daytime extreme sleepiness

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Cataplexia

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Other disease type

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Central nervous system stimulants

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Tricyclic antidepressants

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Sodium oxybate

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Selective serotonin reuptake inhibitor

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Other therapeutic type

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

CHAPTER 6:NARCOLEPSY DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key opportunities and forecast
6.2.2.Market size and forecast, disease type
6.2.3.Market size and forecast, by therapeutic type
6.2.4.Market size and forecast, by country

6.2.4.1.U.S.

6.2.4.1.1.U.S. market size and forecast, by disease type
6.2.4.1.2.U.S. market size and forecast, by therapeutic type

6.2.4.2.Canada

6.2.4.2.1.Canada market size and forecast, by disease type
6.2.4.2.2.Canada market size and forecast, by therapeutic type

6.2.4.3.Mexico

6.2.4.3.1.Mexico market size and forecast, by disease type
6.2.4.3.2.Mexico market size and forecast, by therapeutic type

6.3.Europe

6.3.1.Key opportunities and forecast
6.3.2.Market size and forecast, by disease type
6.3.3.Market size and forecast, by therapeutic type
6.3.4.Market size and forecast, by country

6.3.4.1.Germany

6.3.4.1.1.Germany market size and forecast, by disease type
6.3.4.1.2.Germany market size and forecast, by therapeutic type

6.3.4.2.France

6.3.4.2.1.France market size and forecast, by disease type
6.3.4.2.2.France market size and forecast, by therapeutic type

6.3.4.3.UK

6.3.4.3.1.UK market size and forecast, by disease type
6.3.4.3.2.UK market size and forecast, by therapeutic type

6.3.4.4.Italy

6.3.4.4.1.Italy market size and forecast, by disease type
6.3.4.4.2.Italy market size and forecast, by therapeutic type

6.3.4.5.Spain

6.3.4.5.1.Spain market size and forecast, by disease type
6.3.4.5.2.Spain market size and forecast, by therapeutic type

6.3.4.6.Rest of Europe

6.3.4.6.1.Rest of Europe market size and forecast, by disease type
6.3.4.6.2.Rest of Europe market size and forecast, by therapeutic type

6.4.Asia-Pacific

6.4.1.Key opportunities and forecast
6.4.2.Market size and forecast, by disease type
6.4.3.Market size and forecast, therapeutic type
6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Japan market size and forecast, by disease type
6.4.4.1.2.Japan market size and forecast, by therapeutic type

6.4.4.2.China

6.4.4.2.1.China market size and forecast, by disease type
6.4.4.2.2.China market size and forecast, by therapeutic type

6.4.4.3.Australia

6.4.4.3.1.Australia market size and forecast, by disease type
6.4.4.3.2.Australia market size and forecast, by therapeutic type

6.4.4.4.India

6.4.4.4.1.India market size and forecast, by disease type
6.4.4.4.2.India market size and forecast, by therapeutic type

6.4.4.5.South Korea

6.4.4.5.1.South Korea market size and forecast, by disease type
6.4.4.5.2.South Korea market size and forecast, by therapeutic type

6.4.4.6.Rest of Asia-Pacific

6.4.4.6.1.Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.6.2.Rest of Asia-Pacific market size and forecast, by therapeutic type

6.5.LAMEA

6.5.1.Key opportunities and forecast
6.5.2.Market size and forecast, by disease type
6.5.3.Market size and forecast, by therapeutic type
6.5.4.Market size and forecast, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil market size and forecast, by disease type
6.5.4.1.2.Brazil market size and forecast, by therapeutic type

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia market size and forecast, by disease type
6.5.4.2.2.Saudi Arabia market size and forecast, by therapeutic type

6.5.4.3.South Africa

6.5.4.3.1.South Africa market size and forecast, by disease type
6.5.4.3.2.South Africa market size and forecast, by therapeutic

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA market size and forecast, by disease
6.5.4.4.2.Rest of LAMEA market size and forecast, by therapeutics

CHAPTER 7:COMPANY PROFILES153

7.1.Arena Pharmaceuticals, Inc.

7.1.1.Company overview
7.1.2.Operating business segments
7.1.3.Product portfolio
7.1.4.Business performance

7.2.BIOPROJET COMPANY

7.2.1.Company overview
7.2.2.Operating business segments
7.2.3.Product portfolio

7.3.GRAYMARK HEALTHCARE, INC.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio

7.4.Hikma Pharmaceuticals Plc

7.4.1.Company overview
7.4.2.Operating business segments
7.4.3.Product portfolio
7.4.4.Business performance
7.4.5.Key strategic moves and developments

7.5.JAZZ PHARMACEUTICALS PLC

7.5.1.Company overview
7.5.2.Operating business segments
7.5.3.Product portfolio
7.5.4.Business performance
7.5.5.Key strategic moves and developments

7.6.LIGAND PHARMACEUTICALS, INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.Shionogi Inc.

7.7.1.Company overview
7.7.2.Operating business segments
7.7.3.Product portfolio
7.7.4.Business performance

7.8.Takeda Pharmaceutical Company Limited

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.NOVARTIS INTERNATIONAL AG

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.10.1.Company overvie
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL NARCOLEPSY DRUGS MARKET REVENUE, BY DISEASE, 2020–2030 ($MILLION)
TABLE 02.NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2020–2030 ($MILLION)
TABLE 03.NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, BY REGION, 2020–2030 ($MILLION)
TABLE 04.NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2020–2030 ($MILLION)
TABLE 05.GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 06.NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2020–2030 ($MILLION)
TABLE 07.NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020–2030 ($MILLION)
TABLE 08.SODIUM OXYBATE FOR NARCOLEPSY DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 09.NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2020–2030 ($MILLION)
TABLE 10.NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2020–2030 ($MILLION)
TABLE 11.NARCOLEPSY DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA NARCOLEPSY DRUG MARKET, THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 15.U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 16.U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 17.CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 18.CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 19.MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 20.MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 21.EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 22.EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 23.EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 24.GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 25.GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 26.FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 27.FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 28.UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 29.UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 30.ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 31.ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 32.SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 33.SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 34.REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 35.REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 36.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 37.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 38.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 39.JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 40.JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 41.CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 42.CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 43.AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 44.AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 45.INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 46.INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 47.SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 48.SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 50.REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 51.LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 52.LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 53.LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 55.BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION
TABLE 56.SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 57.SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 58.SOUTH AFRICA NARCOLEPSY DRUG MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 59.SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC, 2020–2030 ($MILLION)
TABLE 60.REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 61.REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 62.ARENA PHARMA: COMPANY SNAPSHOT
TABLE 63.ARENA PHARMA: OPERATING SEGMENTS
TABLE 64.ARENA PHARMA: PRODUCT PORTFOLIO
TABLE 65.BIOPROJET: COMPANY SNAPSHOT
TABLE 66.BIOPROJET: OPERATING SEGMENTS
TABLE 67.BIOPROJET: PRODUCT PORTFOLIO
TABLE 68.GRAYMARK HEALTHCARE: SNAPSHOT
TABLE 69.GRAYMARK HEALTHCARE: OPERATING SEGMENTS
TABLE 70.GRAYMARK HEALTHCARE: PRODUCT PORTFOLIO
TABLE 71.HIKMA: COMPANY SNAPSHOT
TABLE 72.HIKMA: OPERATING SEGMENTs
TABLE 73.HIKMA: PRODUCT PORTFOLIO
TABLE 74.JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 75.JAZZ PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 76.JAZZ PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 77.LIGAND PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 78.LIGAND PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 79.LIGAND PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 80.SHIONOGI: COMPANY SNAPSHOT
TABLE 81.SHIONOGI: OPERATING SEGMENTS
TABLE 82.SHIONOGI: PRODUCT PORTFOLIO
TABLE 83.TAKEDA: COMPANY SNAPSHOT
TABLE 84.TAKEDA: OPERATING SEGMENTS
TABLE 85.TAKEDA: PRODUCT PORTFOLIO
TABLE 86.NOVARTIS: COMPANY SNAPSHOT
TABLE 87.NOVARTIS: OPERATING SEGMENTS
TABLE 88.NOVARTIS: PRODUCT PORTFOLIO
TABLE 89.TEVA: COMPANY SNAPSHOT
TABLE 90.TEVA: OPERATING SEGMENTS
TABLE 91.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.NARCOLEPSY DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW THREAT OF NEW ENTRANTS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITY
FIGURE 13.NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY COUNTRY 2020 & 2030 (%)
FIGURE 17.NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY,  2020 & 2030 (%)
FIGURE 20.NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY COUNTRY, 2020 & 2030 (%)92
FIGURE 21.ARENA PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.HIKMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.HIKMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24.HIKMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25.JAZZ PHARMACEUTICALS: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.JAZZ PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.LIGAND PHARMACEUTICALS: REVENUE, 2018–2020 ($MILLION)
FIGURE 28.LIGAND PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.SHIONOGI: REVENUE, 2018–2020 ($MILLION)
FIGURE 30.SHIONOGI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.SHIONOGI: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 32.TAKEDA: REVENUE, 2018–2020 ($MILLION)
FIGURE 33.TAKEDA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.TAKEDA: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 35.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 37.TEVA: REVENUE, 2018–2020 ($MILLION)
FIGURE 38.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)

 
 

Although narcolepsy is considered an orphan disease, narcolepsy drugs are gaining popularity due to rise in awareness regarding the availability of these drugs that are most commonly used to treat extreme daytime sleepiness and cataplexy. These drugs help improve the quality of sleep of the patient and the overall patient lifestyle. Moreover, these drugs also help in the treatment of similar symptoms that patients are suffering from other types of sleep disorders such as insomnia.

Rise in the cases of narcolepsy across the world is mainly caused due to lack of a brain chemical called "orexin" or "hypocretin" that is responsible for regulating sleep. Factors such as increase in brain tumors, injuries and other diseases associated with brain and rise in awareness among the population regarding narcolepsy are expected to drive the market growth. Furthermore, increase in government initiatives for production of narcolepsy drugs and the launch of its pipeline products is anticipated to boost the expansion of the narcolepsy drug market.

North America leads the narcolepsy drugs market, owing to rise in narcolepsy incidences in the U.S. and increase in government reimbursements on FDA approved prescription medicines in the North American region. Asia-Pacific is expected to experience growth at the fastest CAGR due to increase in overweight populace and rise in demand for effective treatments for narcolepsy.

Another key factor likely to drive the demand for these services is rise in narcolepsy drug issues due to stress, peer pressure, and social & economic hardships. Moreover, a negative work environment can lead to narcolepsy drug problems. Thus, boosting the market growth.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of narcolepsy drugs Market is $2,680.06 million in 2020

A. The forecast period in the report is from 2021 to 2030

A. The market value of narcolepsy drugs Market in 2030 was $6,667.80 Million

A. The base year for the report is 2020

A. Yes, narcolepsy drugs companies are profiled in the report

A. The top companies that hold the market share in narcolepsy drugs Market are Arena Pharmaceuticals, Inc., Bioprojet Company, Graymark Healthcare, Inc., Hikma Pharmaceuticals Plc, Jazz Pharmaceuticals Plc, Ligand Pharmaceuticals, Inc, Shionogi & Co., Ltd, Takeda Pharmaceutical, Novartis International Ag, Teva Pharmaceutical Industries Limited.

A. No, there is no value chain analysis provided in the narcolepsy drugs Market report

A. The key trends in the narcolepsy drugs Market are empowers manufacturers in the medical sector to produce customized products.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Narcolepsy Drugs Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers